Possible Promise
Make Your Future Promise Possible
Source: OpenPR
Biopharmaceuticals and Biomedicine Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
Source: Business Wire
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Five Prime Therapeutics (NasdaqGS: FPRX) to Amgen (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Five Prime will receive only $38.00 in cash for each share of Five Prime that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq
Source: PR Newswire
THOUSAND OAKS, Calif., March 11, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present…
Source: FXNews24
Biotech Stock Roundup: AMGN’s Acquisition, ACAD’s Regulatory Update & More | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
Source: BioWorld
Lured by what Amgen Inc. CEO Bob Bradway called a “compelling opportunity” to strengthen the Thousand Oaks, Calif.-based company’s oncology portfolio and support its international expansion strategy, Amgen on March 4 moved to buy South San Francisco-based Five Prime Therapeutics Inc. for $38 per share, or about $1.9 billion.
Source: Benzinga
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts. Morphic Holding Inc (NASDAQ: MORF ) was among the biggest gainers of the week after the company reported a positive early-stage readout in inflammatory bowel disease patients. M&A momentum continued, as Amgen Inc. (AMGN) announced a deal to buy Five Prime Therapeutics, Inc. (NASDAQ: FPRX ) in an $1.9-billion all-cash deal. Here are the key catalysts for the unfolding week: Conferences Chardan’s 3rd Annual Microbiome Medicines Summit: March 8 H.C. Wainwright Global Life Sciences Conference: March 9-11 Barclays Global Healthcare Conference: March 9-11 15th International Conference on Alzheimer’s and Parkinson’s disease: March 9-14 Clinical Readouts Prothena Corporation plc (NASDAQ: PRTA ) will present at the Alzheimer’s and Parkinson’s disease conference new preclinical data on a treatment for Alzheimer’s disease.
Source: Investing.com
Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Five Prime Therapeutics Inc. Read Zacks Investment Research’s latest article on Investing.com
Source: Smarter Analyst
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology … The post Amgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79% appeared first on Smarter Analyst .
Source: MedCity News
The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series of clinical and financial setbacks that left much of the biotech’s fortunes resting on its lead antibody drug.
Source: The Street
Amgen affirmed its full-year outlook after agreeing to pay $1.9 billion cash for Five Prime in an effort to boost its cancer-drug pipeline.
